The role of SARS-CoV-2 testing in COVID-19

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the novel coronavirus that causes coronavirus disease 2019 (COVID-19) and has escalated, becoming a pandemic in early 2020. Multiple testing modalities have been developed to detect this virus including RT-PCR, antigen, and serology testing. RT-PCR testing is the clinical gold standard and is used for diagnostic purposes of current infections. Antigen testing is rapid and requires significantly less equipment, but lacks the sensitivity of RT-PCR testing. Serology assays detect antibodies raised against SARS-CoV-2, so only detect prior exposure. It is important to note that use of antibody tests may also detect prior asymptomatic infections. For these reasons, it is imperative that all testing modalities be continuously developed and improved to better our understanding of disease transmission, helping to inform and change infection control policies and protecting both employees in the workplace and patients. We aim to quantify the seroprevalence of anti-SARS-CoV-2 IgG in the healthcare workers at Boston Medical Center, including those with asymptomatic infections. Our results show an overall seroprevalence of 5.5% with an asymptomatic seroprevalence of 1.8%. High risk groups include those who are obese, smokers, and Hispanic/LatinX. Experiencing some symptoms was associated with a higher risk of seropositivity, as was lack of social distancing amongst coworkers. In a separate study, we aim to assess the direct antigen rapid tests (DART) created by E25Bio in patients seeking care at Boston Medical Center. This study has been significantly limited by number of participants, as recruitment has been paused during both COVID-19 surges in Boston, MA. The current data shows poor positive agreement between DART and RT-PCR, but acceptable negative agreement. Each testing modality works to fill in the gaps of knowledge that still persist around SARS-CoV-2. Each of these testing types provides a unique piece of information and when used together, will help to inform strategies to overcome the SARS-CoV-2 pandemic

Emerg Infect Dis

Emerging Infectious Diseases is providing access to these abstracts on behalf of the ICEID 2022 program committee (http://www.iceid.org), which performed peer review. ICEID is organized by the Centers for Disease Control and Prevention and Task Force for Global Health, Inc.Emerging Infectious Diseases has not edited or proofread these materials and is not responsible for inaccuracies or omissions. All information is subject to change. Comments and corrections should be brought to the attention of the authors.Suggested citation: Authors. Title [abstract]. International Conference on Emerging Infectious Diseases 2022 poster and oral presentation abstracts. Emerg Infect Dis. 2022 Sep [date cited]. http://www.cdc.gov/EID/pdfs/ICEID2022.pdf2022PMC94238981187

Emerging infectious diseases

Emerging Infectious Diseases is providing access to these abstracts on behalf of the ICEID 2012 program committee (www.iceid.org), which performed peer review. Emerging Infectious Diseases has not edited or proofread these materials and is not responsible for inaccuracies or omissions. All information is subject to change. Comments and corrections should be brought to the attention of the authors.Influenza preparedness: lessons learned -- Policy implications and infectious diseases -- Improving preparedness for infectious diseases -- New or rapid diagnostics -- Foodborne and waterborne infections -- Effective and sustainable surveillance platforms -- Healthcare-associated infections -- Molecular epidemiology -- Antimicrobial resistance -- Tropical infections and parasitic diseases -- H1N1 influenza -- Risk Assessment -- Laboratory Support -- Zoonotic and Animal Diseases -- Viral Hepatitis -- E1. Zoonotic and animal diseases -- E2. Vaccine issues -- E3. H1N1 influenza -- E4. Novel surveillance systems -- E5. Antimicrobial resistance -- E6. Late-breakers I -- Antimicrobial resistance -- Influenza preparedness: lessons learned -- Zoonotic and animal diseases -- Improving preparedness for infectious diseases -- Laboratory support -- Early warning systems -- H1N1 influenza -- Policy implications and infectious diseases -- Modeling -- Molecular epidemiology -- Novel surveillance systems -- Tropical infections and parasitic diseases -- Strengthening public health systems -- Immigrant and refugee health -- Foodborne and waterborne infections -- Healthcare-associated infections -- Foodborne and waterborne infections -- New or rapid diagnostics -- Improving global health equity for infectious diseases -- Vulnerable populations -- Novel agents of public health importance -- Influenza preparedness: lessons learned -- Molecular epidemiology -- Zoonotic and animal diseases -- Vaccine-preventable diseases -- Outbreak investigation: lab and epi response -- H1N1 influenza -- laboratory support -- effective and sustainable surveillance platforms -- new vaccines -- vector-borne diseases and climate change -- travelers' health -- J1. Vectorborne diseases and climate change -- J2. Policy implications and infectious diseases -- J3. Influenza preparedness: lessons learned -- J4. Effective and sustainable surveillance platforms -- J5. Outbreak investigation: lab and epi response I -- J6. Late-breakers II -- Strengthening public health systems -- Bacterial/viral coinfections -- H1N1 influenza -- Novel agents of public health importance -- Foodborne and waterborne infections -- New challenges for old vaccines -- Vectorborne diseases and climate change -- Novel surveillance systems -- Geographic information systems (GIS) -- Improving global health equity for infectious diseases -- Vaccine preventable diseases -- Vulnerable populations -- Laboratory support -- Prevention challenges for respiratory diseases -- Zoonotic and animal diseases -- Outbreak investigation: lab and epi response -- Vectorborne diseases and climate change -- Outbreak investigation: lab and epi response -- Laboratory proficiency testing/quality assurance -- Effective and sustainable surveillance platforms -- Sexually transmitted diseases -- H1N1 influenza -- Surveillance of vaccine-preventable diseases -- Foodborne and waterborne infections -- Role of health communication -- Emerging opportunistic infections -- Host and microbial genetics -- Respiratory infections in special populations -- Zoonotic and animal diseases -- Laboratory support -- Antimicrobial resistance -- Vulnerable populations -- Global vaccine initiatives -- Tuberculosis -- Prevention challenges for respiratory diseases -- Infectious causes of chronic diseases -- O1. Outbreak investigation: lab and epi response II -- O2. Prevention challenges for respiratory diseases -- O3. Populations at high risk for infectious diseases -- O4. Foodborne and waterborne infections -- O5. Laboratory support: surveillance and monitoring infections -- O6. Late-breakers IIIAbstracts published in advance of the conference

Emerging infectious diseases

Emerging Infectious Diseases is providing access to these abstracts on behalf of the ICEID 2008 program committee, which performed peer review. Emerging Infectious Diseases has not edited or proofread these materials and is not responsible for inaccuracies or omissions. All information is subject to change.Comments and corrections should be brought to the attention of the authors.Slide Sessions -- Foodborne & waterborne diseases I -- Influenza I -- Surveillance: International -- Zoonotic & animal diseases I -- Methicillin-resistant stapylococcal infections -- Vectorborne diseases -- Foodborne & waterborne diseases II -- Influenza II -- Surveillance: Domestic -- Zoonotic & animal diseases II -- Noscomial infections -- Respiratory diseases -- Health communications -- Blood, organ, & tissue safety -- Tropical diseases -- New rapid diagnostics -- Mobile populations & infectious diseases -- Vaccine-preventable diseases -- Tuberculosis -- Sexually transmitted diseases -- -- Poster Abstracts -- Vaccines & vaccine-preventable diseases -- Antimicrobial resistance -- Climate changes -- Foodborne & waterborne infections -- Health communication -- Infectious causes of chronic diseases -- Influenza -- New or rapid diagnostics -- Nosocomial infections -- Outbreak investigation: Lab & epi response -- Sexually transmitted diseases -- Surveillance: International & new strategies -- Travelers' health & disease importation -- Tropical infections & parasitic diseases -- Vector-borne diseases -- Women, gender, sexual minorities & infectious diseases -- Zoonotic & animal diseases -- Vaccines & vaccine-preventable diseases -- Antimicrobial resistance -- Emerging aspects of HIV -- Foodborne & waterborne infections -- Health communication -- Molecular epidemiology -- Outbreak investigation: Lab & epi response -- Poverty & infectious diseases -- Surveillance: International & new strategies -- Tropical infections & parasitic diseases -- Vector-borne diseases -- Zoonotic & animal diseases -- Vaccines & vaccine-preventable diseases -- Antimicrobial resistance -- Blood, organ, & other tissue safety -- Foodborne & waterborne infections -- Host & microbial genetics -- Influenza -- Molecular epidemiology -- New or rapid diagnostics -- Outbreak investigation: Lab & epi response -- Prevention effectiveness, cost effectiveness, & cost studies -- Surveillance: International & new strategies -- Vector-borne diseases -- Zoonotic & animal diseases -- Vaccines & vaccine-preventable diseases -- Antimicrobial resistance -- Bioterrorism preparedness -- Emerging opportunistic infections -- Foodborne & waterborne infections -- Healthcare worker safety -- Influenza -- Laboratory proficiency testing/quality assurance -- Modeling -- Nosocomial infections -- Outbreak investigation: Lab & epi response -- Vector-borne diseases -- Viral hepatitis -- Zoonotic & animal diseases -- Vaccines & vaccine-preventable diseases -- Antimicrobial resistance -- Emerging opportunistic infections -- Foodborne & waterborne infections -- Influenza -- New or rapid diagnostics -- Nosocomial infections -- Outbreak investigation: Lab & epi response -- Social determinants of infectious disease disparities -- Surveillance: International & new strategies -- Tuberculosis -- Vector-borne diseases -- Zoonotic & animal diseases -- -- Additional Poster Abstracts.Abstracts published in advance of the conference

A Meeting of Minds: In Recognition of the Contributions of Randall J. Cohrs

A Special Issue in memory of Randall J. Cohrs, Ph.D. Topics include original research reports on a variety of viruses as well as reviews and commentaries on Randy’s contributions to many investigations

Drug development progress in duchenne muscular dystrophy

Duchenne muscular dystrophy (DMD) is a severe, progressive, and incurable X-linked disorder caused by mutations in the dystrophin gene. Patients with DMD have an absence of functional dystrophin protein, which results in chronic damage of muscle fibers during contraction, thus leading to deterioration of muscle quality and loss of muscle mass over time. Although there is currently no cure for DMD, improvements in treatment care and management could delay disease progression and improve quality of life, thereby prolonging life expectancy for these patients. Furthermore, active research efforts are ongoing to develop therapeutic strategies that target dystrophin deficiency, such as gene replacement therapies, exon skipping, and readthrough therapy, as well as strategies that target secondary pathology of DMD, such as novel anti-inflammatory compounds, myostatin inhibitors, and cardioprotective compounds. Furthermore, longitudinal modeling approaches have been used to characterize the progression of MRI and functional endpoints for predictive purposes to inform Go/No Go decisions in drug development. This review showcases approved drugs or drug candidates along their development paths and also provides information on primary endpoints and enrollment size of Ph2/3 and Ph3 trials in the DMD space